The claim rests on three assertions: that Trump and Musk cut PEPFAR, that the program has saved more than 26 million African lives, and that those people are now dying as a result.
On the first point, the record is clear. Beginning on the first day of his second term, President Trump signed executive actions that paused foreign aid, froze payments, and ultimately led to the dissolution of USAID, the agency that administered the majority of PEPFAR's bilateral programming. Research from KFF found that 71% of HIV-related global health awards were terminated, and that PEPFAR implementers reported mass staff layoffs, halted services, and confusion about which activities were still permitted. A State Department waiver issued in early February allowed some treatment and care programs to continue, but it excluded most prevention services, including pre-exposure prophylaxis for the general population. Reporting by The Guardian described the immediate fallout: in Mozambique, the number of people receiving PrEP dropped from 30,000 to 19,000; in Zimbabwe, from 4,000 to 1,800. UNAIDS projected that if PEPFAR treatment and prevention services were stopped entirely, an additional 6.6 million HIV infections could occur by 2029.
The claim that Musk was personally responsible is more contestable. Musk, leading DOGE, boasted of having "fed USAID into the wood chipper" and publicly denied cutting HIV programs, but global health officials directly tied the agency's dismantling and resulting chaos to his team's actions. His role is a matter of emphasis rather than invention.
On the 26 million figure, both KFF and academic researchers at The Conversation confirm that PEPFAR is credited with saving 26 million lives since its launch in 2003. However, that figure is global, not Africa-specific, even though sub-Saharan Africa is by far the largest beneficiary. The post's framing implies the count refers to Africa alone, which is an overstatement of the geography though not of the scale.
The assertion that those patients are "already dying" is the hardest to verify directly. The available evidence shows treatment interruptions, layoff of health workers, and reduced access to medicines and diagnostics, all of which are well-documented. Modeling studies estimate that ending PEPFAR funding could result in 565,000 new HIV infections over ten years in sub-Saharan Africa. But reports of actual increased mortality specifically tied to the cuts are limited; the claim leans on reasonable inference from the disruption rather than confirmed death tolls.
PEPFAR itself was not eliminated. The FY 2025 continuing resolution maintained level funding of $4.85 billion, and Congress later exempted PEPFAR from a rescission package. The more accurate description is that PEPFAR was severely disrupted, with its implementation capacity gutted, rather than simply "cut." The post's language overstates the situation, but the underlying story of a program under unprecedented stress is well-supported.
